REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Regenxbio's enterprise value was $353.27M on Nov 11, 2026, against $375.79M a year earlier. Over the last 5 years it ranged from $80.64M to $864.49M, with a median of $302.35M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $353.27M | -17.3% |
| 2025 | Dec 31, 2025 | $426.91M | +309.3% |
| 2024 | Dec 31, 2024 | $104.30M | -75.5% |
| 2023 | Dec 29, 2023 | $425.14M | +16.5% |
| 2022 | Dec 30, 2022 | $364.86M | -57.8% |
| 2021 | Dec 31, 2021 | $864.49M | -38.6% |
| 2020 | Dec 31, 2020 | $1.41B | +28.8% |
| 2019 | Dec 31, 2019 | $1.09B | +6.8% |
| 2018 | Dec 31, 2018 | $1.02B | +21.3% |
| 2017 | Dec 29, 2017 | $843.27M | +175.4% |
| 2016 | Dec 30, 2016 | $306.25M | +37.1% |
| 2015 | Dec 31, 2015 | $223.33M | – |
See a number that looks wrong?